Clinical trial · Observational
Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis
A Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA) treated at Peking Union Medical College Hospital from July 15, 2017 to July 15, 2019. The formalin fixed paraffin-embedded tissues from patients pathologically diagnosed with adenomyosis during this time period were also included as control specimens. The eutopic endometrium, normal adenomyosis tissue, and EC-AIA tissue were harvested from the FFPE tissue from patients with EC-AIA. The normal eutopic endometrium and normal adenomyosis tissue were obtained by laser microdissection. The driving genes and potential molecular mechanism of EC-AIA will be found by the technology of whole exome sequencing and transcriptomics (RNA-sequencing).
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenomyosis | — | UNRESOLVED | — |
| Ectopic Endometrial Tissue | — | UNRESOLVED | — |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Eutopic Endometrium | — | UNRESOLVED | — |
| Genomics | — | UNRESOLVED | — |
| Transcriptomics | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| whole exome sequencing and RNA-sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Endometrial carcinoma arising in adenomyosis
- description
- Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
- interventionNames
- Genetic: whole exome sequencing and RNA-sequencing
- label
- Adenomyosis without malignancy
- description
- Patients pathologically diagnosed with adenomyosis
- interventionNames
- Genetic: whole exome sequencing and RNA-sequencing
Primary outcomes (2)
- measure
- Frequencies of somatic driving mutations
- timeFrame
- One year
- description
- The differences of distributions and frequencies of somatic driving mutations will be compared between eutopic ectopic endometrium, and cancer tissues by whole exome sequencing
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological confirmed diagnosis with atypical hyperplasia and malignant transformation of adenomyosis glandular epithelium (including endometrioid, serous and clear cell carcinoma), with or without concurrent endometrial carcinoma * Signed an approved informed consents Exclusion Criteria: * Not meeting all the inclusion criteria. * The formalin fixed paraffin-embedded (FFPE) tissue was not acquired at the required time period. * The patients enrolled had accompanied some other kinds of carcinoma (such as ovarian cancer, cervical cancer, primary peritoneal cancer). * Patients had cancer history of certain organ (such as colorectal cancer, gastric cancer, etc.)
References
Publications (0)
Data not yet available